| 国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析 |
| |
| 引用本文： | 范琳,刘一典,肖和平. 国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析[J]. 中国防痨杂志, 2020, 42(2): 91-94. DOI: 10.3969/j.issn.1000-6621.2020.02.003 |
| |
| 作者姓名： | 范琳 刘一典 肖和平 |
| |
| 作者单位： | 200433.同济大学附属上海市肺科医院结核病临床研究中心 上海市结核病(肺)重点实验室 |
| |
| 摘 要： | 作者针对国内《耐药结核病化学治疗指南(2019年)》(简称“《指南(2019)》”)与《中国耐多药结核病和利福平耐药结核病治疗专家共识(2019年版)》的异同进行具体分析,并与WHO相关指南进行比对,从药物的分组、抗结核治疗的实施路径、《指南(2019)》的特色与国内耐药结核病治疗研究的发展方向等方面进行阐述,为临床一线医师对指南的理解提供思路。
|
| 关 键 词： | 结核 抗多种药物性 利福平 总结性报告(主题) 指南 评论 |
| 收稿时间： | 2019-12-21 |
Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus |
| |
| FAN Lin,LIU Yi-dian,XIAO He-ping. Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus[J]. The Journal of The Chinese Antituberculosis Association, 2020, 42(2): 91-94. DOI: 10.3969/j.issn.1000-6621.2020.02.003 |
| |
| Authors: | FAN Lin LIU Yi-dian XIAO He-ping |
| |
| Affiliation: | Shanghai Pulmonary Hospital, Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Tongji University School of Medicine, Shanghai 200433,China |
| |
| Abstract: | Authors made analysis on the similarities and differences of Chinese Guidelines on chemotherapy of drug-resistant tuberculosis (2019) (abbreviated as “Guidelines 2019”) and Chinese consensus on multidrug-resistant tuberculosis and rifampin resistant tuberculosis treatment (2019 edition) and compared with WHO guidelines, provided the ideas from the elaboration on drug groups divided, implement approach of anti-TB treatment,the characteristics of Guidelines 2019 and future development direction of national drug-resistant treatment for clinical physicians. |
| |
| Keywords: | Tuberculosis multidrug-resistant Rifampin Consensus development conferences as topic Guidebooks Comment |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国防痨杂志》浏览原始摘要信息 |
|
点击此处可从《中国防痨杂志》下载全文 |
